Enterovirus 71 (EV71), a member of the enterovirus A species of the family Picornaviridae, is the most common pathogen of hand, foot, and mouth disease (HFMD) in children and infants (1, 2). Enteroviruses are a group of naked positive single-stranded RNA viruses, and their genome comprises a 5’ untranslated region (UTR), structural polypeptide P1, nonstructural polypeptides P2 and P3, and a 3’ untranslated region (3). Based on phylogenetic analysis of the VP1 genes, worldwide EV71 strains were classified into 3 main genogroups (A, B, and C) and 12 subgenotypes (A, B0 to B5, and C1 to C5) (4–6). Epidemic waves of EV71 infections have swept through countries in the Asia-Pacific region since 1997 (7, 8). Although the globally emerging pathogen coxsackievirus A6 (CV-A6) has tended to predominate over EV71 as the etiologic agent of HFMD since 2013, EV71 is still responsible for severe HFMD and even death (9–11).

From March 2014 to September 2014, the Shenzhen Center for Disease Control and Prevention (CDC) received death reports of eight children with severe HFMD infections. Fecal specimens or anal swabs from these cases were archived at the Department of Microbiology, Shenzhen CDC. Seven of 8 specimens (87.5%) were detected as positive for EV71 by real-time reverse transcription-PCR (RT-PCR), and the other specimen (1/8 [12.5%]) was detected as positive for CV-A16 (12). Next, these strains were isolated by culturing clinical samples in rhabdomyosarcoma (RD) cell lines. Detailed epidemiological data for seven fatal EV71 strains are listed in Table 1.

A pair of universal primers, EVA-F30 (5’-TAAAAACAGCCT GTGGGTGTACCCACCCA-3’) and EVA-R36 (5’-GCTATTCT GTTTATAAATTTACCCACCGTTC-3’), were used to amplify full-length genomes of these strains by a one-step RT-PCR method, as described previously (12). Amplified DNA products were sequenced by TaKaRa (Japan) using a primer-walking method. Contigs were assembled using sequencer version 4.9. The raw genome sequences were examined using BioEdit version 7.2.5 before submission to GenBank. Molecular phylogeny was investigated using the program MEGA 6.06 (13).

The complete genome sequences of seven EV71 strains were composed of 7,405 nucleotides (nt), excluding the poly(A) tail. The 5’-UTR was found to be 742 nt, followed by an open reading frame (ORF) encoding the structural protein P1 (2,586 nt), the nonstructural proteins P2 (1,734 nt) and P3 (2,259 nt), and the 3’-UTR (81 nt). The contents of A, C, G, and U of the seven EV71 genome sequences were 27.05 to 27.27%, 23.97 to 24.19%, 23.70 to 23.92%, and 24.83 to 25.02%, respectively, with G + C contents

| Isolate | Gender | Age (yr) | Clinical manifestation | Accession no. |
|---------|--------|---------|------------------------|---------------|
| EV71/SZ04/CHN/2014 | Female | 1.6 | Fever; rash; vesicles on hands and buttocks; pharyngalgia; lethargy; polyneia; rapid heart rate; muscle twitching; abnormal eye movements; and aseptic encephalitis | KT428644 |
| EV71/SZ07/CHN/2014 | Female | 1.2 | Fever; rash; polyneia; cold limbs; shock; and bronchopneumonia | KT428645 |
| EV71/SZ12/CHN/2014 | Male | 2.5 | Fever; rash; vesicles on hands, foot, and mouth; polyneia; and aseptic encephalitis | KT428646 |
| EV71/SZ25/CHN/2014 | Male | 2.6 | Fever; rash; vesicles on hands, foot, and mouth; polyneia; rapid heart rate; and muscle twitching | KT428647 |
| EV71/SZ42/CHN/2014 | Male | 4.3 | Fever; vesicles on hands, foot, mouth, knees, and buttocks | KT428648 |
| EV71/SZ50/CHN/2014 | Male | 3.0 | Fever; rash; vesicles on hands, foot, and buttocks; muscle twitching | KT428649 |
| EV71/SZ88/CHN/2014 | Male | 1.9 | Fever; rash; vesicles on hands, foot, mouth, elbow, knees, and buttocks; cough; lethargy; polyneia; rapid heart rate; muscle twitching; and aseptic encephalitis | KT428650 |
of 47.67 to 48.11%. The full-length genome sequences of these strains displayed close relationships to native EV71 strains and showed 94.2 to 99.8% identity to each other. All of these strains were assigned to subgenotype C4a based on phylogenetic analysis of the VP1 gene.

To date, a vaccine against EV71 has not been commercially introduced (14, 15), but family- and kindergarten-based early intervention programs and timely treatment may reduce the incidence of severe and fatal cases.

**Nucleotide sequence accession numbers.** The full-length genome sequences of seven fatal EV71 isolates have been deposited in GenBank under the accession numbers listed in Table 1.

**ACKNOWLEDGMENTS**

Funding for this research was provided by the Shenzhen Center for Disease Control and Prevention, Shenzhen, China. The views and conclusions from this report are those of the authors and do not necessarily represent the official opinion of Shenzhen CDC.

We are grateful to the pediatricians who are from the sentinel surveillance system for HFMD in Shenzhen, China.

**REFERENCES**

1. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. 2010. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 9:1097–1105. [http://dx.doi.org/10.1016/S1474-4422(10)70209-X](http://dx.doi.org/10.1016/S1474-4422(10)70209-X).

2. Tapparel C, Siegrist F, Petty TJ, Kaiser L. 2013. Picornavirus and enterovirus diversity with associated human diseases. Infect Genet Evol 14: 282–293. [http://dx.doi.org/10.1016/j.meegid.2012.10.016](http://dx.doi.org/10.1016/j.meegid.2012.10.016).

3. Oderste MS, Peharanda S, Maher K, Pallansch MA. 2004. Complete genome sequences of all members of the species human enterovirus A. J Gen Virol 85:1597–1607. [http://dx.doi.org/10.1099/vir.0.79789-0](http://dx.doi.org/10.1099/vir.0.79789-0).

4. Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, Takebe Y, Pybus OG. 2010. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 84:3339–3350. [http://dx.doi.org/10.1128/JVI.01019-09](http://dx.doi.org/10.1128/JVI.01019-09).

5. Van der Sanden S, van der Avoort H, Lemey P, Uslu G, Koopmans M. 2010. Evolutionary trajectory of the VP1 gene of human enterovirus 71 genogroup B and C viruses. J Gen Virol 91:1949–1958. [http://dx.doi.org/10.1099/vir.0.019695-0](http://dx.doi.org/10.1099/vir.0.019695-0).

6. Hassel C, Mirand A, Lukashev A, TerletskaiaLadwig E, Farkas A, Schuffenecker I, Diedrich S, Huemer HF, Archimbaud C, Peigee-Lafeuille H, Hensquell G, Bailly JL. 2015. Transmission patterns of human enterovirus 71 to, from and among European countries, 2003 to 2013. Euro Surveill 20 pii:21218. [http://dx.doi.org/10.3390/v7122947](http://dx.doi.org/10.3390/v7122947).

7. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778–790. [http://dx.doi.org/10.1016/S1473-3099(10)70194-8](http://dx.doi.org/10.1016/S1473-3099(10)70194-8).

8. Zhuang ZC, Kou ZQ, Bai YJ, Cong X, Wang LH, Li C, Zhao L, Yu XJ, Wang ZY, Wen HL. 2015. Epidemiological research on hand, foot, and mouth disease in mainland China. Viruses 7:6400–6411. [http://dx.doi.org/10.3390/v7122947](http://dx.doi.org/10.3390/v7122947).

9. Zeng H, Lu J, Zheng H, Yi L, Guo X, Liu L, Rutherford S, Sun L, Tan X, Li H, Ke C, Lin J. 2015. The epidemiological study of coxsackievirus A6 revealing hand, foot and mouth disease epidemic patterns in Guangdong, China. Sci Rep 5:10550. [http://dx.doi.org/10.1038/srep10550](http://dx.doi.org/10.1038/srep10550).

10. Bian L, Wang Y, Yao X, Mao Q, Xu M, Liang Z. 2015. Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti Infect Ther 13:1061–1071.

11. Huang Y, Zhou Y, Lu H, Yang H, Feng Q, Dai Y, Chen L, Yu S, Yao X, Zhang H, Jiang M, Wang Y, Han N, Hu G, He Y. 2015. Characterization of severe hand, foot, and mouth disease in Shenzhen, China, 2009–2013. J Med Virol 87:1471–1479. [http://dx.doi.org/10.1002/jmv.24200](http://dx.doi.org/10.1002/jmv.24200).

12. Chen L, Yang H, Feng QJ, Yao XJ, Zhang HL, Zhang RL, He YQ. 2015. Complete genome sequence of a coxsackievirus A16 strain, isolated from a fatal case in Shenzhen, southern China, in 2014. Genome Announc 3(2): e00391-15. [http://dx.doi.org/10.1128/genomeA.00391-15](http://dx.doi.org/10.1128/genomeA.00391-15).

13. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 30: 2725–2729. [http://dx.doi.org/10.1093/molbev/msr197](http://dx.doi.org/10.1093/molbev/msr197).

14. Ng Q, He F, Kwang J. 2015. Recent progress towards novel EV71 anti-therapeutics and vaccines. Viruses 7:6441–6457. [http://dx.doi.org/10.1038/mobevests1197](http://dx.doi.org/10.1038/mobevests1197).

15. Mao QY, Wang Y, Bian L, Xu M, Liang Z. 2016. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines 14:1–8. [http://dx.doi.org/10.1586/14760584.2016.1138862](http://dx.doi.org/10.1586/14760584.2016.1138862).